First Gene Therapy Product Could Enter Market in Q1 2018
FDA Approves Gene Therapy Application for Rare Genetic Blindness
The U.S. Food and Drug Administration (FDA) has approved an application for a ground breaking gene therapy aimed at treating a rare genetic form of blindness caused by a gene mutation. This therapy has the potential to be a one-time treatment, offering patients a near-curative option. If all goes according to plan, the first gene therapy could reach the market as early as January 2018.
Read more: https://www.biopharmadive.com/news/spark-therapeutics-first-gene-therapy-blindness-january-market/447223/
